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fast pretreatment or real-time quality assurance. The purpose of this study is to test a 2D silicon detector, 
MagicPlate-512 (MP512), in a complex clinical environment involving real-time reconfiguration of the MLC 
leaves during target tracking. Methods: MP512 was placed in the center of a solid water phantom and 
mounted on a motion platform used to simulate three different patient motions. Electromagnetic target 
tracking was implemented using the Calypso system (Varian Medical Systems, Palo Alto, CA, USA) and an 
MLC tracking software. A two-arc VMAT plan was delivered and 2D dose distributions were reconstructed 
by MP512, EBT3 film, and the Eclipse treatment planning system (TPS). Dose maps were compared using 
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inf and lateral directions to show the agreement of MP512 to EBT3 and to highlight the efficacy of the 
MLC tracking system in mitigating the effect of the simulated patient motion. Results: Using a 3%/3 mm 
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nearly 2 mm (with respect to the no-motion case); however, the MLC tracking strategy was able to 
mitigate 80% of this effect. Conclusions: MP512 is capable of high spatial resolution 2D dose 
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tool for 2D small field dosimetry and pretreatment quality assurance for MLC tracking modalities. These 
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Purpose: Radiation treatments delivered with real-time multileaf collimator (MLC) track-
ing currently lack fast pretreatment or real-time quality assurance. The purpose of this
study is to test a 2D silicon detector, MagicPlate-512 (MP512), in a complex clinical envi-
ronment involving real-time reconfiguration of the MLC leaves during target tracking.
Methods: MP512 was placed in the center of a solid water phantom and mounted
on a motion platform used to simulate three different patient motions. Electromag-
netic target tracking was implemented using the Calypso system (Varian Medical
Systems, Palo Alto, CA, USA) and an MLC tracking software. A two-arc VMAT plan
was delivered and 2D dose distributions were reconstructed by MP512, EBT3 film,
and the Eclipse treatment planning system (TPS). Dose maps were compared using
gamma analysis with 2%/2 mm and 3%/3 mm acceptance criteria. Dose profiles
were generated in sup-inf and lateral directions to show the agreement of MP512
to EBT3 and to highlight the efficacy of the MLC tracking system in mitigating the
effect of the simulated patient motion.
Results: Using a 3%/3 mm acceptance criterion for 2D gamma analysis, MP512 to
EBT3 film agreement was 99% and MP512 to TPS agreement was 100%. For a 2%/
2 mm criterion, the agreement was 95% and 98%, respectively. Full width at half
maximum and 80%/20% penumbral width of the MP512 and EBT3 dose profiles
agreed within 1 mm and 0.5 mm, respectively. Patient motion increased the mea-
sured dose profile penumbral width by nearly 2 mm (with respect to the no-motion
case); however, the MLC tracking strategy was able to mitigate 80% of this effect.
Conclusions: MP512 is capable of high spatial resolution 2D dose reconstruction
during adaptive MLC tracking, including arc deliveries. It shows potential as an
effective tool for 2D small field dosimetry and pretreatment quality assurance for
MLC tracking modalities. These results provide confidence that detector-based pre-
treatment dosimetry is clinically feasible despite fast real-time MLC reconfigurations.
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1 | INTRODUCTION
Stereotactic body radiation therapy (SBRT), stereotactic ablative
radiotherapy (SABR), and stereotactic radiosurgery (SRS) are highly
conformal radiotherapy modalities for small tumors and functional
abnormalities. They use a high dose per fraction (from 3 to 20 Gy)
and fewer fractions than conventional external beam radiotherapy
(EBRT) over the course of treatment. Field sizes are also typically
smaller than conventional radiotherapy, commonly less than
4 9 4 cm2, where effects such as the loss of charged particle equi-
librium (CPE) and partial source occlusion are present.
SABR is often used to treat early-stage lung tumors.1 Patient res-
piration has been reported to affect target position by up to 30 mm
during EBRT.2 Intrafraction tumor motion can have a considerable
impact on the dose delivered to the tumor volume and surrounding
healthy tissue,3 if motion is not compensated. Careful quality assur-
ance processes are essential in the application of such highly confor-
mal radiotherapy modalities when tumor motion is present.4
Intrafraction tumor motion can be accommodated in the treat-
ment planning process using an extra margin called the internal target
volume (ITV). This margin encompasses the entire volume occupied
by the moving tumor throughout several breathing cycles, obtained
from 4DCT data. Inclusion of an ITV generally leads to a larger plan-
ning target volume (PTV) and as a result, there is often more healthy
tissue irradiated compared to a treatment experiencing minimal
tumor motion. Another approach to manage organ motion is gating
the beam to treat only when the tumor is in a particular position.5-7
Real-time adaptive radiotherapy (ART) aims to treat the target vol-
ume with sensible margin reduction, in comparison to an ITV contour-
ing, by monitoring the position and shape of the tumor continuously
throughout the treatment in order to modify the beam in real time.8
The aim is to reduce the size of the ITV considerably, so that
healthy tissue receives minimal dose, while at the same time deliver-
ing the correct dose to the target to achieve the highest possible
therapeutic outcome.
Kilovoltage Intrafraction Monitoring (KIM) is one real-time moni-
toring technique9; it uses the gantry equipped kV x-ray imager to
monitor the position of the tumor in real time during treatment. An
algorithm calculates the difference in tumor position from the cur-
rent and previous image to predict the target position in 3D. When
the tumor moves outside a predefined tolerance, the treatment is
paused and the patient is repositioned through use of couch motion
prior to resuming treatment.
There are several other possible strategies to manage patient
motion during EBRT, including pretreatment and intratreatment
imaging, respiratory control devices or robotic couches.
Recently, an extensive review was published of current motion
management strategies applied in the clinic.10
An alternative motion management approach in real-time ART
uses Calypso, the electromagnetic guided tumor tracking adopted by
Varian, and real-time beam modulation using the multileaf collimator
(MLC). The Calypso system detects and reconstructs the position of
electromagnetic beacons implanted in proximity of the tumor vol-
ume.11,12
The combination of Calypso and MLC tracking has been imple-
mented clinically at Royal North Shore Hospital (Sydney–Australia)
as a real-time tumor monitoring solution for ART. In 2013, MLC
tracking was used for the first time during a prostate VMAT treat-
ment13 and more recently with lung SABR.14 In that study, the dose
distribution was recalculated on the patient CT dataset using a
motion encoded treatment plan derived from analysis of the treat-
ment log files (dynalog). Results showed a reduction in the PTV size
by up to 40% and a reduction of mean dose to normal lung tissue of
30%, compared to a standard ITV-based delivery.14
Tracking techniques such as KIM and radiofrequency tracking
use feedback systems that may induce a signal in the chosen
dosimeter, i.e., kV x rays and RF electromagnetic radiation, respec-
tively. It is important that the dosimeter used during real-time ART
is also unperturbed by these additional signals and only measures
the dose due to the MV treatment.
Small radiation fields introduce some extra dosimetry require-
ments compared to larger fields. Namely high spatial resolution of
the detector array for use in steep dose gradients as well as small
sensitive volume of a single detector, compared to beam size, to
avoid volume averaging. The adopted dosimeter system should ide-
ally be close to tissue equivalent, so as not to perturb the
beam.15,16
There are several dosimeters that can potentially be used for
small field dosimetry, each with their advantages and disadvantages.
EBT3 film and Fricke or polymer-based gel have the required spa-
tial resolution for small field dosimetry. They can give 2D and 3D dose
information, respectively; however, they lack a real-time readout.16,17
Ionization chambers can be read out in real time and can be cali-
brated for absolute dose; however, their spatial resolution and vol-
ume averaging effects can limit their use in high-resolution arrays for
small field dosimetry.16
Silicon diodes can be fabricated with a small sensitive volume;
this means they can form 2D arrays with high spatial resolution. The
density of silicon is considerably higher than that of water, so energy
dependence needs to be characterized as well as dose rate and
angular dependence.18
Log file analysis is a reasonable machine QA tool for MLC and
gantry positional errors. However, it is unable to provide information
on the position of a moving phantom relative to the beam or inde-
pendently evaluate the performance of an external tracking system,
such as Calypso.
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The Centre for Medical Radiation Physics (CMRP) at University
of Wollongong has developed a 2D monolithic silicon diode array
detector to be used for QA of small field real-time ART: MagicPlate-
512 (MP512). It has been designed to independently monitor exter-
nal beam radiotherapy treatments under complex clinical conditions
and reconstruct dose distributions in real time. It is capable of pulse-
by-pulse monitoring of the linac beam and has a spatial resolution
suitable for small field dosimetry. It has been rigorously characterized
for basic square fields in terms of percentage depth dose, output
factor, beam profiles, dose per pulse, and dose linearity.19 It has also
been used with modulated IMRT fields, with a fixed gantry angle
and a single patient motion applied.20 This study shows dosimetric
results from MP512 using a two-arc VMAT delivery with realistic
patient motions and tracking by the means of the Calypso localiza-
tion system. Dose was delivered to a solid water phantom for three
different patient motion traces obtained by 4DCT at Royal North
Shore Hospital (Sydney–Australia). Dose maps obtained from MP512
were compared to EBT3 film and treatment planning system
calculations.
2 | MATERIALS AND METHODS
MP512 was placed in a solid water phantom on top of a movable
platform. Three patient motion traces were supplied to the platform
to simulate clinical lung motion during treatment delivery. Calypso
(Varian Medical Systems, Palo Alto, CA, USA) was used to monitor
the position of the phantom and real-time MLC tracking was used. A
two-arc VMAT plan was delivered for various motion modalities.
Dose was monitored in real-time with MP512 and compared to
EBT3 film and the treatment planning system. Each component of
the experiment is described in more detail below.
2.A | MP512 detector array
MP512 (Figure 1) features a 52 9 52 mm2 array of 512 individual
ion implanted silicon diodes on an epitaxial p-type silicon substrate.
Each diode has a sensitive area of 0.5 9 0.5 mm2 with 2 mm cen-
ter-to-center distance. The detector is assembled on a 500 lm thick
printed circuit board which allows for mechanical rigidity and con-
nection of the readout electronics.
MP512 is a monolithic silicon detector which has an intrinsic
asymmetric structure creating an angular dependence, which needs
to be considered. Angular correction factors for 6 MV photons on a
Varian 2100iX linac have previously been obtained.21 The correction
is valid for all MP512 devices; individual diode sensitivity is cor-
rected pixel-by-pixel by a flat field prior to measurements. The rota-
tion of the linac was independently monitored by an inclinometer
positioned on the gantry and synchronized with the data acquisition
system. This allowed for on-line correction of the detector response
frame-by-frame.
To calibrate the detector, a dose linearity measurement in the
dose range 50 cGy to 1000 cGy was delivered at dmax in solid water
for a 10 9 10 cm2 field size with 6 MV photons from a Varian
2100iX linac. Detector charge (nC) was plotted against dose (cGy)
and the slope of the linear relationship was used to define the dose
calibration factor.
The data acquisition system (DAQ) of the detector comprises of
an analog front end (AFE) connected to an analog to digital con-
verter. These are controlled by a field programmable gate array
(FPGA) which also provides the de-randomization of the detector
channels, acquisition of the data from the inclinometer and data
packing for the USB2.0 interface used to communicate with a stan-
dard laptop. The AFE is a commercial chip from Texas Instruments
(Dallas, USA), the AFE0064, and features 64 current integrators
whose output is proportional to the charge collected on a variable
capacitor over a user-defined integration time window. The DAQ
features eight AFE chips, which are parallelized to readout the entire
detector at a maximum frame frequency of 7 kHz. The system can
be synchronized with the linac electron gun pulse, so that current is
integrated only when the beam is on, minimizing noise and allowing
for measurement of the dose delivered by every linac pulse. Full
specifications and benchmarking of the DAQ have been published
by Fuduli et al.22
A software control panel for the instrument was designed in
house using the Qt Creator Integrated Development Environment
(IDE) (The Qt Company — Espoo, Finland) based on C++. It manages
all communication with the FPGA including definition of the integra-
tion time, dynamic range, acquisition time, and frequency of mea-
surements. It also provides real-time visualization of the detector
response and allows for retrospective analysis of the data acquired.
2.B | Reproducing organ motion
The patient lung motions were simulated using the 6D Hexamotion
movable platform by ScandiDos (Uppsala, Sweden) which provides
simultaneous motion in each of the x (left-right), y (sup-inf), and z
(ant-post) directions. Motion patterns were supplied by Northern
Sydney Cancer Centre (Royal North Shore Hospital, St Leonards
NSW) and were extracted from patient 4DCT data. For this study,
three motion patterns were used:
1. Patient 1: Lung trace with approximately 8 mm sup-inf offset
2. Patient 2: Lung trace centered around zero (null sup-inf offset)
F I G . 1 . Rendering of MP512 detector mounted on printed circuit
board (PCB) and encapsulated in a PMMA phantom.
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3. Patient 3: Lung trace with a predominant component in the lat-
eral direction.
These motion traces were chosen as they represent three unique
types of respiration.
Figure 2 shows the motion traces as a function of time for each
patient in x, y, and z directions for approximately 80 s, correspond-
ing to the time required to deliver the planned dose to the target.
2.C | Motion tracking
MLC tracking is performed using the Calypso 4D localization system
(Varian Medical Systems — Palo Alto, CA, USA) for real-time moni-
toring of the target motion in conjunction with an MLC driving soft-
ware developed at University of Sydney.23 Electromagnetic beacons
are used to determine the target position, this information is used
by the tracking software to signal the MLC controller to configure
the field shape in response to the detected motion of the target.13
Two different algorithms were input to the MLC controller: passive
feedback and predictive feedback. The passive feedback algorithm
calculates the position of the moving target based on information
from Calypso, and instructs the MLC controller to reconfigure the
beam aperture accordingly. There is a measurable latency of approxi-
mately 230 ms 13 between detection by Calypso and actuation of
the MLC leaves due to computation time and finite leaf speed,
meaning that the beam lags behind the real target trajectory. The
predictive feedback algorithm uses kernel density estimation23 and a
short learning time frame in order to approximate the position of the
target, based on the difference between nominal and effective tumor
position. By predicting the target position at a time of T þ s (where
T is current time and s is a small increment of time) and setting
s ¼ 230 ms, the system latency is almost eliminated.20,24
Four tracking modalities were used to study the effect of motion
on the dose distribution:
1. No motion: phantom is static throughout the treatment delivery
2. Motion with no tracking: the phantom follows the supplied
motion trace and no MLC tracking is applied
3. Motion with passive tracking: the supplied motion trace is
adopted by the phantom and the MLC motion is controlled by
Calypso
4. Motion with predictive tracking: the phantom follows the sup-
plied motion trace, Calypso tracking is activated and the predic-
tive algorithm is used23 to minimize the delay between detected
motion and the corresponding MLC movement.
2.D | Detector encapsulation and phantom
MP512 was encased between two 5 mm thick sheets of PMMA for
structural rigidity (see Figure 1). There is an air gap above the sensi-
tive volume to match the detector response to that of EBT3 film for
small field beams down to 1 9 1 cm 19,25 and to minimize the den-
sity and perturbation effects of silicon.26,27
An aluminum shielding box of 2 mm thickness was designed to
mitigate the baseline fluctuations due to the electromagnetic (EM)
field generated by Calypso.20 The time-varying EM field induced a
current in the wiring and DAQ electronics, which contributed to
fluctuations of the baseline signal (noise). The aluminum box covered
and sealed the entire detector and data acquisition system. Its effect
on dosimetry has been investigated by the means of Geant4 and
proved experimentally to have negligible effects at 1.5 cm water
equivalent depth and below.20 The phantom geometry is such that
the minimum thickness of solid water in the beams eye view is
1.5 cm throughout each arc.
The aluminum box was designed to allow 5 mm of solid water to
be placed on top of the detector phantom, producing a water equiv-
alent depth of approximately 1.5 cm, to simulate for example a chest
wall. The calculation of the water equivalent depth of the detector
(with beam normally incident to phantom surface, gantry at zero) is
shown in Eq. (1) where ti and qi are the thickness and density of
F I G . 2 . Three-dimensional lung motion traces corresponding to (a)
Patient 1, (b) Patient 2 and (c) Patient 3. Data are from 4DCT
sampled every 25 ms. X component corresponds to motion in left-
right direction, Y component corresponds to motion in sup-inf
direction, and Z corresponds to motion in ant-pos direction.
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each of the materials, respectively. Data used in the calculation are




ti  qi ¼ 15:27 mm
Equation 1: Calculation of water equivalent depth
The aluminum box was placed above 5 cm of solid water, fig-
ure 3 shows the cross-section of the detector phantom with the alu-
minum sheets and solid water blocks in place.
2.E | Treatment planning and delivery
Two VMAT arcs were used to deliver 496 MU and 508 MU at
6 MV on a Varian Clinac iX. The first arc started at gantry angle 150
degrees, rotated in a counter-clockwise direction and stopped at 340
degrees, the second arc started at 340 degrees, rotated clockwise
and returned to 150 degrees. This beam arrangement allowed suffi-
cient target coverage while avoiding the treatment couch. A gross
tumor volume (GTV) was contoured manually around a hypothetical
spherical target of 2 cm diameter. The target’s center was aligned
with the central pixel of the detector. A PTV was defined as a 3 mm
expansion of the GTV to create a clinically relevant lung plan while
allowing the contours to remain within the phantom geometry. The
Eclipse Treatment Planning System (TPS) (Varian Medical Systems —
Palo Alto, CA, USA), at Northern Sydney Cancer Centre was used to
generate a treatment plan which was inversely calculated on the CT
dataset of the phantom (Figure 4). A dose prescription of 5 Gy in a
single fraction was implemented. CT slice thickness was 1 mm and
dose was calculated using a 2-mm dose grid. No density overrides
were applied as there were no appreciable artifacts in the dataset.
Note that the same plan was delivered for all motion modalities, i.e.,
there was no ITV-based plan used for comparison. The aim of this
work was to characterize MP512 for use in adaptive arc modalities
using MLC tracking and gantry rotation. There was no intention to
comment on the effectiveness of MLC tracking versus ITV-based
planning in terms of clinical outcomes; hence, the same plan was
used for all modalities.
In Figure 4, a slice of the CT dataset incorporating the GTV and
PTV margins is shown. Figure 5 depicts the 2D dose map from
Eclipse overlaid on MP512 from a beam’s eye view (coronal plane).
The square regions overlaid on Figure 5 highlight the sensitive area
of the detector and correspond to the dose map position extracted
for comparison with the experimental results.
2.F | Dosimetric measurements
EBT3 film was used to verify dose accuracy utilizing a gamma anal-
ysis of the 2D dose distributions. To coregister the dose maps, film
sheets were sliced to the dimensions of the silicon detector and
inserted into the PMMA phantom. The airgap recess in the PMMA
phantom was common to both the detector and film, so dose maps
were intrinsically coregistered. MATLAB was used to convert the
optical density of the films to dose using a set of calibration films.21
Local gamma analysis was performed using a MATLAB script.
Gamma pass rates are reported for 2%/2 mm and 3%/3 mm dose
difference and distance to agreement criteria. The same method
was adopted to compare MP512 dose maps to the extracted 2D
dose maps from the TPS. Finally, a comparison was made of
MP512 dose maps for all motion modalities with respect to the no-
motion case to quantify the accuracy in reconstructing the effects
of MLC tracking.
Dose profiles in the sup-inf and left-right (lateral) directions for
MP512 and EBT3 were plotted on the same axis for each motion
modality. The profiles were fitted with a shape preserving polynomial
interpolation in MATLAB and aligned to 50% of the central axis dose
response. The fit allows for accurate calculation of the full width at
half maximum (FWHM) and left and right penumbral width, i.e.,
width of the profile between 80% response and 20% response. The
fitting step used is 20 lm and the estimated accuracy for determina-
tion of the FWHM and penumbra width is approximately
0.25 mm. This corresponds to physical size of a single silicon
diode, which is approximately 0.5 9 0.5 mm2.
The baseline noise of the detector signal was determined to be
approximately 1%, the dose uncertainty of the EBT3 film was cal-
culated19 to be approximately 2% and error bars are reported on
the dose profiles, accordingly.
TA B L E 1 Data for calculating water equivalent depth of the
detector sensitive volume.
Material Thickness (ti) mm Density (qi) g/cm
3
PMMA 4 1.18
Solid Water 5 1.03
Aluminum 2 2.7
F I G . 3 . Cross-section of scattering
conditions of the solid water phantom.
Units are mm. Detector surface is at an
approximate water equivalent depth of
1.5 cm and the solid PMMA phantom is
encapsulated by aluminum to minimize
induced noise from RF field of Calypso.
Coordinate system is marked with the Y
direction coming out of the page.
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The effect of motion on dose response was analyzed by plotting
the point-to-point dose difference to show the areas of under and
over dose and to highlight the effect that each tracking modality had
on reducing these errors.
3 | RESULTS
3.A | Dose linearity
The response of MP512 to accumulated dose is shown in Figure 6.
The relationship of charge to dose in the 50 to 1000 cGy range is
linear. The MP512 measured charge is converted to dose using slope
of the linearity curve.
3.B | Gamma analysis
The integral dose maps obtained from EBT3, MP512, and TPS
are shown in Figure 7. Angular corrections were applied
frame-by-frame to the MP512 response before integrating the
dose.
The gamma pass rates comparing EBT3 to MP512 and TPS
to MP512 for the no-motion case are shown in Table 2.
Table 3 shows the gamma analysis results for the three motion
patterns in respect to the no-motion case as measured by
MP512.
3.C | Dose profiles measured by MP512 and EBT3
film
In Figure 8, the dose profiles are illustrated in the vertical and hori-
zontal directions of MP512 and EBT3 film for each of the motion
F I G . 4 . GTV (blue) and PTV (red)
margins defined on a CT dataset of the
detector phantom represented in a
transverse plane view. Directions are
indicated with Y (sup-inf) coming out of
page.
F I G . 5 . 2D dose map extracted from
Eclipse TPS overlaid on CT slice of MP512.
Boxes highlight the sensitive area of the
detector and represent the dose map
region used for gamma analysis
comparison (coronal plane views).
F I G . 6 . Linear dose response exhibited by MP512 for cumulative
dose delivery. The slope of the linear fit is used to convert measured
detector charge (nC) to absorbed dose (cGy). Error bars indicate
measured baseline fluctuation of 1%.
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modalities. The uncertainty in EBT3 film measurement was calcu-
lated19 to be 2% and is within the size of the data points. Analysis
of the baseline fluctuation of MP512 produces an uncertainty of
1%. Table 4 summarizes the analysis of the FWHM and penumbral
width for the dose profiles for the sup-inf direction.
3.D | MP512 motion profiles
The profiles shown in Figure 9 highlight the effect of Patient 1
motion on the dose distribution. The profiles are reconstructed from
MP512 for each motion modality. They are plotted on a single axis
and the point-to-point dose difference is included in both cGy and
percentage to highlight areas of under and over dosage. The dose
difference is referenced to the baseline no-motion case. The same
profiles are generated for Patients 2 and 3 in Figs 10 and 11,
respectively.
4 | DISCUSSION
Gamma analysis of the 2D dose maps from MP512 showed a very
close match to the 2D dose measured from EBT3 film and dose
extracted from Eclipse TPS. Using a 2%/2 mm acceptance criteria,
the response of MP512 matched that of EBT3 for 95% of points
and TPS for 98% of points. When a 3%/3 mm acceptance criterion
was used, the agreement was 99% and 100% for EBT3 and TPS,
respectively. This confirms the accuracy of MP512 as a 2D dosime-
try system even under complex clinical conditions. MP512 can
reconstruct the dose delivered during realistic patient breathing with
real-time MLC tracking and full arc delivery. As a result, MP512 can
be used as a tool to quantify the efficacy of a particular tracking
regime, and in patient-specific pretreatment QA.
Gamma analysis was also performed on the MP512 measured
dose maps to intercompare each motion modality, this gives some
insight into the effect of MLC tracking.
Patient 1 motion (with no tracking) resulted in a pass rate of
78% (2%/2 mm); however, the two tracking modalities brought the
pass rate to 95% or above for both 3%/3 mm and 2%/2 mm accep-
tance criteria.
Patient 2 uncorrected motion had a pass rate of 55% (2%/2 mm)
and Patient 3 had 80% pass rate (2%/2 mm) with motion. When
tracking was applied, pass rates of above 93% were observed for
both Patient 2 and Patient 3 for both criteria.
Gamma pass rates above 95% for 3%/3mm agreement are com-
monly accepted as sufficient to proceed with treatment.28 In our
case when the Patient 1 motion pattern was introduced, there was a
large drop in the 2%/2 mm pass rate when no tracking is applied;
however, the 3%/3 mm criteria was relatively unchanged at 98%. If
a gamma analysis using 3%/3mm acceptance criteria was the only
form of pretreatment QA for this plan, it appears to be clinically
acceptable. However, it is somewhat unlikely as this plan was
designed to be used in conjunction with MLC tracking and would
not be used clinically when no tracking is to be applied, rather an
ITV-based plan would be created. This result still highlights the need
to use caution when depending solely on gamma analysis (especially
with a rather loose acceptance criterion) as a form of pretreatment
SPT215PMmliF3TBE
(a) (b) (c)
F I G . 7 . 2D integral dose maps reconstructed from (a) EBT3, (b) MP512 and (c) TPS for the no-motion case.
TA B L E 3 Gamma pass rates for MP512 vs MP512 response with
respect to the no-motion case for each motion modality
Motion trace Tracking modality 2%-2mm (%) 3%-3mm (%)
Patient 1 No tracking 78.65 98.44
Passive 98.96 99.83
Predictive 98.44 99.65
Patient 2 No tracking 55.56 75.35
Passive 94.62 97.05
Predictive 96.01 98.09
Patient 3 No tracking 79.69 91.32
Passive 95.66 98.61
Predictive 93.23 96.35
TA B L E 2 Gamma pass rates for MP512 compared to TPS and
EBT3. Dose maps used correspond to the no-motion case
Tracking modality Comparison 2%-2mm (%) 3%-3mm (%)
No-motion TPS to MP512 98.44 100
EBT3 to MP512 95.31 99.31









F I G . 8 . MP512 vs EBT3 Dose Profiles
for various motion modalities with Patient
1 motion applied. Left Column: Profiles in
the sup-inf direction. Right Column:
Profiles in the left-right direction.
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QA. A similar conclusion was reached in previous studies29,30 which
showed that gamma analysis pass rates for 3%/3 mm and 2%/2mm
acceptance criteria for particular 2D dose planes had very little
correlation to errors in clinically relevant patient DVH metrics and
even a 1%/1mm acceptance criteria only showed moderate
correlation.
MP512 monitors the beam in real time, for every linac pulse. As
a result, the data are available immediately after the measurement.
This information can be used to give insight into the efficacy of a
particular tracking regime. For example, the results from the gamma
analysis show the predictive tracking algorithm did not always lead
to a higher pass rate when compared to passive tracking, in this case
it was particularly dependent on the type of motion being experi-
enced by the target volume.
In our study, for periodic motion patterns, the predictive algo-
rithm had superior performance and gave better target tracking;
however, for motion patterns that are aperiodic and erratic the pas-
sive tracking gave better results. We hypothesize this is due to the
difficulty in accurately predicting an irregular signal and depends on
the type and duration of the learning process adopted in the predic-
tive algorithm.31 Some algorithms use an initial learning window
before treatment where the program learns the breathing trace over
a few respiratory cycles and others employ a dynamic type of learn-
ing which can adapt faster to irregularities in the motion.32
Dose profiles from MP512 and EBT3 film undergoing Patient 1
motion were plotted on a single axis and compared (Figure 8). It was
TA B L E 4 Summary of the comparison of FWHM and left and right













No-motion EBT3 23.9 3.7 4.2
MP512 24.5 4.1 4.7
TPS 23.7 4.1 4.7
Motion EBT3 24.0 5.3 5.4
MP512 24.6 5.7 5.9
Difference 0.6 0.3 0.5
Passive tracking EBT3 23.8 4.7 5.3
MP512 24.6 4.7 5.3
Difference 0.8 0 0
Predictive
tracking
EBT3 23.8 4.3 5.3
MP512 24.7 4.4 5.4
Difference 0.9 0.1 0.1
F I G . 9 . Dose profiles measured with MP512 when the Patient 1 motion was applied for each motion modality, with dose error. Left
corresponds to Sup-Inf direction and right corresponds to Left-Right direction. In the error plots, NM corresponds to no motion, M to motion,
MT to motion tracking (i.e., passive algorithm) and MTP to motion tracking with prediction.
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found that in the sup-inf direction (major axis of organ motion due
to the breathing cycle), the penumbral width of both profiles was
within 0.5 mm and FWHM agrees within 1 mm for all deliveries.
The agreement of data between MP512 and EBT3 film over multiple
datasets further proves the accuracy of MP512 for use in adaptive
therapy treatments.
MP512 measured dose profiles from each motion modality
were plotted on a single axis, this allowed a qualitative overview
of the effect of patient motion and MLC tracking on the dose
delivered. The effect of Patient 1 (Figure 9) motion on the dose
distribution can clearly be identified through the spread of the
profile and loss of the dose distribution shape presented in the
no-motion case. The discrepancy is quantified by an increase in
left penumbral width of 1.62 mm compared to the no-motion
case. Passive tracking was able to reduce the penumbral width by
60%. The predictive algorithm showed a reduction of 79%, an
agreement within 0.34 mm of the no-motion case. The motion
trace for Patient 1 is primarily in the vertical direction with a
maximum lateral displacement of approximately 1.5 mm
(Figure 2a); because the lateral shift is smaller than the MLC leaf
width, it produces very little change in the profiles along the
horizontal direction and the tracking is not able to compensate
for it.
Point-to-point dose difference plots were included to highlight
the dose error (in cGy and %) as a function of distance across the
profile. This allowed for a quantitative measure of dose errors and
their locations, introduced by patient motion, and show the effec-
tiveness of the tracking system in reducing areas of under and over
dose. When motion was applied, there were under dose and over
dose regions of up to 280 cGy (45% of max dose) and 200 cGy
(35% of max dose) measured respectively, for a single fraction. The
predictive tracking algorithm allowed the MLC to effectively com-
pensate for the motion, the dose discrepancies were reduced to just
30 cGy which is 4.5% of the maximum dose. This represents a
reduction in dose error of up to 90% when tracking is applied com-
pared to the no-motion case.
The effect of Patient 2 motion on the dose distribution is plotted
in Figure 10. The motion profile is highly distorted with a triangular
shape and large areas of under and over dose, up to  200 cGy.
These dose errors are halved from 20% of maximum dose to around
10% when tracking is applied. There is not much effect from the
motion along the horizontal component due to the small contribu-
tion of the motion in this direction.
Figure 11 shows the dose profile when Patient 3 motion trace
was applied. Due to the predominantly left-right component of this
breathing pattern, the vertical profile is not largely affected;
F I G . 1 0 . Dose profiles measured with MP512 when the Patient 2 motion was applied for each motion modality, with dose error. Left
corresponds to vertical direction and right corresponds to horizontal direction. In the error plots, NM corresponds to no motion, M to motion,
MT to motion tracking (i.e., passive algorithm) and MTP to motion tracking with prediction.
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however, there is an overdose of 8% on the central axis in this direc-
tion when no tracking is applied which is reduced slightly to around
6% when tracking is activated.
The shift of the dose in the horizontal direction is evident in
this case due to the large lateral component of the motion trace.
Although the MP512 sensitive area is not large enough to
reconstruct the full dose profile in this direction, the effect of
motion causing distortion of the profile exemplifies the benefits of
tracking.
5 | CONCLUSIONS
CMRP has developed MP512, a 2D silicon diode array for use in
small field dosimetry. It consists of 512 individual ion implanted
diodes of size 0.5 9 0.5 mm2 with 2 mm center-to-center distance.
In this study, a two-arc VMAT treatment was delivered to the
phantom and MP512’s angular dependence was corrected frame-by-
frame. MP512 response was comparable to EBT3 film and the calcu-
lated TPS dose. These results provide confidence that detector-
based pretreatment dosimetry is clinically feasible despite fast real-
time MLC reconfigurations.
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